Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9323256 | 1.00 | TBXAS1 (0.31) | TBXAS1PTPRA | |
| SCHEMBL27693420 | 0.89 | — | — | |
| SCHEMBL22711564 | 0.87 | — | — | |
| SCHEMBL14362213 | 0.87 | — | — | |
| SCHEMBL7695097 | 0.85 | — | — | |
| SCHEMBL4184564 | 0.85 | — | — | |
| SCHEMBL4184560 | 0.85 | — | — | |
| SCHEMBL198655 | 0.84 | ALDH1A1 (0.33) | — | |
| SCHEMBL17610495 | 0.84 | ALDH1A1 (0.33) | — | |
| SCHEMBL198654 | 0.84 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | claimed |
| EP-4319795-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | Avantor Performance Materials, LLC (US) | 2024-02-14 | — | — | EP | claimed |
| CN-117355321-A | Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents | 安万托特性材料股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| WO-2022217021-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2022-10-13 | — | — | WO | claimed |
| EP-0579823-A1 | NEW HEXAPEPTIDIC DERIVATIVES, PREPARATION, METHOD AND APPLICATION AS MEDICAMENTS OF SAID NEW DERIVATIVES | ROUSSEL UCLAF (FR) | 1994-01-26 | — | — | EP | claimed |
| WO-1993016104-A1 | NEW HEXAPEPTIDIC DERIVATIVES, PREPARATION, METHOD AND APPLICATION AS MEDICAMENTS OF SAID NEW DERIVATIVES | ROUSSEL-UCLAF (FR) | 1993-08-19 | — | — | WO | claimed |
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4319795-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | Avantor Performance Materials, LLC (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319795-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | Avantor Performance Materials, LLC (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117355321-A | Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents | 安万托特性材料股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117355321-A | Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents | 安万托特性材料股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022217021-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022217021-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-0579823-A1 | NEW HEXAPEPTIDIC DERIVATIVES, PREPARATION, METHOD AND APPLICATION AS MEDICAMENTS OF SAID NEW DERIVATIVES | ROUSSEL UCLAF (FR) | 1994-01-26 | — | — | EP | disclosed |
| EP-0579823-A1 | NEW HEXAPEPTIDIC DERIVATIVES, PREPARATION, METHOD AND APPLICATION AS MEDICAMENTS OF SAID NEW DERIVATIVES | ROUSSEL UCLAF (FR) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993016104-A1 | NEW HEXAPEPTIDIC DERIVATIVES, PREPARATION, METHOD AND APPLICATION AS MEDICAMENTS OF SAID NEW DERIVATIVES | ROUSSEL-UCLAF (FR) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993016104-A1 | NEW HEXAPEPTIDIC DERIVATIVES, PREPARATION, METHOD AND APPLICATION AS MEDICAMENTS OF SAID NEW DERIVATIVES | ROUSSEL-UCLAF (FR) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AADAT, KYNU, PNISR | TBXAS1 2496/4885PTPRA 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.